We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+42.67%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.86B
AUM Growth
+$458M
Cap. Flow
+$125M
Cap. Flow %
6.71%
Top 10 Hldgs %
60.44%
Holding
79
New
30
Increased
3
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
SPRY icon
ARS Pharmaceuticals
SPRY
+$84.6M
2
STTK icon
Shattuck Labs
STTK
+$79M
3
SLDB icon
Solid Biosciences
SLDB
+$33.6M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$18.9M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.9M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$99.6M
2
STRO icon
Sutro Biopharma
STRO
+$50M
3
SURF
Surface Oncology, Inc. Common Stock
SURF
+$28.5M
4
ASMB icon
Assembly Biosciences
ASMB
+$24.9M
5
CBIO
Crescent Biopharma
CBIO
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.73%
2 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNCE
51
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.13M 0.11%
+10,000
New +$2.08M
EUCRU
52
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.13M 0.11%
+200,000
New +$2.03M
CHFW.U
53
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$2.09M 0.11%
+200,000
New +$2.04M
FLACU
54
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$2.08M 0.11%
+200,000
New +$2.09M
FVAM
55
DELISTED
5:01 Acquisition Corp
FVAM
$2.03M 0.11%
+200,000
New +$2.02M
STRO icon
56
Sutro Biopharma
STRO
$386M
$2.03M 0.11%
9,342
-302,020
-97% -$50M
RPTX
57
DELISTED
Repare Therapeutics
RPTX
$1.72M 0.09%
50,000
– –
BCAB icon
58
BioAtla
BCAB
$5.34M
$1.7M 0.09%
+1,000
New +$1.67M
CMAXW
59
DELISTED
CareMax, Inc. Warrant
CMAXW
$1.56M 0.08%
+100,000
New +$220K
MGTX icon
60
MeiraGTx Holdings
MGTX
$1.08B
$1.44M 0.08%
94,819
– –
TMPMU
61
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
$1.03M 0.06%
+100,000
New +$1.01M
KNTE
62
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$995K 0.05%
+25,000
New +$1M
ICPT
63
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$625K 0.03%
25,300
– –
SURF
64
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$449K 0.02%
48,558
-3,284,619
-99% -$28.5M
ASMB icon
65
CALL
Assembly Biosciences
ASMB
$498M
$108K 0.01%
1,483
– –
ASMB icon
66
Assembly Biosciences
ASMB
$498M
– –
-212,365
Closed -$24.9M
CBIO
67
CALL
Crescent Biopharma
CBIO
$546M
– –
-8,500
Closed -$2.61M
CBIO
68
Crescent Biopharma
CBIO
$546M
– –
-37,252
Closed -$11.4M
IRWD icon
69
CALL
Ironwood Pharmaceuticals
IRWD
$586M
– –
-500,000
Closed -$4.5M
RPRX icon
70
Royalty Pharma
RPRX
$26.2B
– –
-50,000
Closed -$2.1M
SVRA icon
71
Savara
SVRA
$1.08B
– –
-56,500
Closed -$62K
UBX
72
DELISTED
Unity Biotechnology
UBX
– –
-29,600
Closed -$1.02M
XCUR icon
73
Exicure
XCUR
$11M
– –
-6,785
Closed -$1.78M
XOMA
74
DELISTED
Xoma
XOMA
– –
-50,809
Closed -$957K
CNST
75
CALL
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-400,000
Closed -$8.1M
1 2
3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2020 Portfolio in Review

As of Q4 2020, EcoR1 Capital held 79 positions worth $1.86B, up 33% from $1.4B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

EcoR1 Capital deployed $125M of net new capital in Q4 2020, opening 30 new positions and adding to 3 existing holdings. Its largest new stake was ARS Pharmaceuticals: 2,533,635 shares worth $117M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 96% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Kura Oncology, an estimated $99.6M trimmed.

  • EcoR1 Capital's largest Q4 2020 buy was ARS Pharmaceuticals: 2,533,635 shares worth $117M.
  • EcoR1 Capital added most to Oric Pharmaceuticals in Q4 2020, an estimated $12.9M increase.
  • EcoR1 Capital's biggest Q4 2020 reduction was Kura Oncology, cutting an estimated $99.6M.
  • EcoR1 Capital fully exited Assembly Biosciences in Q4 2020, selling an estimated $24.9M.
  • EcoR1 Capital's ten largest holdings make up 60% of its $1.86B portfolio in Q4 2020.
  • EcoR1 Capital opened 30 new positions and closed 14 in Q4 2020.
  • EcoR1 Capital's portfolio value rose 33% quarter-over-quarter to $1.86B.

Based on EcoR1 Capital's 13F filing for Q4 2020, filed 16 Feb 2021.